08:57 AM EDT, 07/18/2025 (MT Newswires) -- Telomir Pharmaceuticals ( TELO ) shares climbed by nearly 150% in premarket activity Friday after the company said its lead candidate Telomir-1 may help restore a tumor suppressor in human prostate cancer cells.

New preclinical results showed that Telomir-1 reversed epigenetic silencing through DNA methylation of the tumor suppressor and immune response regulator STAT1 gene, whose frequent silencing in advanced cancers disrupts immune detection and apoptotic pathways, Telomir said.

The study showed that Telomir-1 fully reversed STAT1 hypermethylation in tumor tissue, the company said, adding that the Paclitaxel group showed no such reversal and Rapamycin showed partial demethylation.

The company added that Telomir-1 also lowered hypermethylation of the pro-apoptotic tumor suppressor TMS1 commonly silenced in prostate cancer.

Telomir noted that even though Paclitaxel and Rapamycin had comparable or greater effects on TMS1 methylation, Telomir-1 can modulate STAT1 and TMS1, which together regulate immune response and apoptosis.